# Peak sales, royalty rates and milestone payments explained
A biotech CEO walks into a licensing negotiation with a Phase 2 asset and walks out with a headline: "$1.2 billion deal." The upfront cash payment, the part that actually hits the bank account, is often just $50 to $80 million. The rest is a chain of "if this works" payments stretched over a decade. Understanding that gap is the single most useful skill for reading pharma deal news.
This lesson walks through a realistic term sheet and shows how to calculate the real value of a licensing deal, and how royalty tiers are built around peak sales estimates.
Pharma licensing deals (where a large company, the "licensee," pays a smaller company, the "licensor," for rights to develop and sell a drug) are structured in layers:
The "deal value" reported in press releases (e.g., "$1.2 billion deal") is the sum of upfront plus *all possible* milestones, sometimes including royalties as a rough estimate. Most of these milestones never get paid, because most drugs fail somewhere in development. Only around 10 to 12% of drugs entering Phase 1 trials eventually reach approval, according to a widely cited
So a $1.2 billion "deal" might realistically deliver $200 to $400 million to the licensor if the drug fails at Phase 3, or the full amount only if it becomes a blockbuster with sales above $1 billion a year.
Let's build a simplified, realistic licensing term sheet for a hypothetical mid-stage oncology asset (numbers illustrative, structured to match typical 2024 to 2025 deal patterns):
| Component | Amount | Trigger |
|---|---|---|
| Upfront payment | $75 million | Signing |
| Development milestone 1 | $50 million | Start of Phase 3 trial |
| Development milestone 2 | $100 million | Regulatory filing (NDA/BLA submission to FDA, the US Food and Drug Administration, or MAA to EMA, the European Medicines Agency) |
| Regulatory milestone | $150 million | FDA approval |
| Regulatory milestone (EU) | $75 million | EMA approval |
| Sales milestone 1 | $200 million | Annual net sales exceed $500 million |
| Sales milestone 2 | $350 million | Annual net sales exceed $1 billion |
| Royalty tier | 8% to 16% | Tiered on net sales, see below |
Total potential deal value (upfront + all milestones): $75M + $50M + $100M + $150M + $75M + $200M + $350M = $1,000 million ($1 billion), before royalties.
This is the number in the press release. Note that $825 million of it (82%) is contingent on outcomes that are uncertain and sequential: you cannot hit the sales milestones without first clearing every development and regulatory milestone.
To sanity-check the headline number, apply success probabilities at each stage (illustrative, based on general oncology industry benchmarks, estimate):
Rough expected value of the milestone payments (multiplying each payment by its cumulative probability of being reached) will typically come out well under half of the "total deal value." This is why analysts distinguish between total deal value (headline) and risk-adjusted deal value (realistic).
Royalties matter more than milestones for a drug that succeeds, because they run for the life of patent protection, often 10+ years post-launch.
Royalty rates in pharma licensing typically range from 5% to 20% of net sales, and are almost always tiered: the rate increases as sales climb. A simplified structure:
Worked calculation: if the drug achieves $1.3 billion in annual net sales:
That $148 million recurs every year sales stay near that level, for as long as patent or regulatory exclusivity lasts. Compare that to the $350 million one-time sales milestone: the royalty stream can exceed total milestone value within two to three years for a genuine blockbuster.
"Peak sales" is the projected maximum annual revenue a drug will reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → before patent expiry or competitive erosion. It's the single most-quoted, most-debated figure in pharma finance, because it drives:
Peak sales estimates come from analysts modeling: target patient population, likely pricing, market sharemarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.View full definition → versus competitors, and geographic rollout (US typically launches first and carries higher list prices; European peak sales are usually lower per-country due to centralized price negotiation with national health systems, though the EU market in aggregate is large).
For context on scale: in 2024, several individual drugs (e.g., Keytruda, Merck's oncology drug) posted single-product annual sales above $25 billion globally (estimate, per company 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition → filings). Most licensed assets never approach that; a "successful" specialty drug peak sales range is more commonly $500 million to $3 billion a year (estimate, general industry range).
This asymmetry is why licensing deals often carve out separate royalty rates or milestone tranches for US versus ex-US approval.
Knowledge check
1. Why do headline pharma licensing deal values, like a widely reported '$1.2 billion deal,' typically overstate the money that actually changes hands?
2. In a pharma licensing deal, what fundamentally distinguishes a milestone payment from a royalty?
3. A biotech company is evaluating two licensing offers with identical total 'headline' deal values. Which additional piece of information would be most useful for judging which deal is actually more valuable to the licensor?
4. Select ALL correct answers about the components of a typical pharma licensing deal.
Select all the correct answers.
5. Select ALL correct answers about why understanding the gap between headline deal value and realistic payout matters when reading pharma deal news.
Select all the correct answers.
Next time you see a headline like "Company X licenses asset to Company Y in deal worth up to $2 billion," apply this checklist:
1. Find the upfront cash figure, usually stated separately, this is the only guaranteed money.
2. Note what fraction is development milestones (near-term, higher probability) versus sales milestones (long-term, low probability, only matters if the drug is a hit).
3. Check if royalty rates are disclosed. Many deals don't disclose exact tiers; "tiered royalties" without numbers means treat as unknown.
4. Ask: does the deal split rights by geography (e.g., US rights retained, ex-US licensed)? This changes who captures peak sales value where.
🎬 [VIDEO: "How Pharma Licensing Deals Actually Work" - youtube.com/results?search_query=pharma+licensing+deal+structure+explained - search for recent explainer content walking through real deal structures and milestone mechanics]